MRK

Merck & Co., Inc.

Healthcare · NYSE · Market cap $357.9bn

$145.95

as of 16 Oct 2026, 7% below its 52-week high

Screens as reasonably placed to keep growing its dividend, with low cut-risk signals. Its valuation looks somewhat extended against its own history.

These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.

Trailing yield: 2.33%Last 12 months of regular payments at today's price
Forward yield: 2.46%Each payment expected in the next 12 months, not the latest one doubled
Earnings cover: 0.38×Pays 262% of earnings
Cash cover: 1.9×Free cash flow over dividends paid
5y dividend growth: +5.8% a yearNo cut since FY2008
Next ex-dividend date: Estimated15 Dec 2026Quarterly dividend of about $0.90

Compared with US companies in Drug Manufacturers - General (9)

Trailing yield is higher than 5 of the 8 other US companies in Drug Manufacturers - General.
5y dividend growth (as paid) is lower than 4 of the 7 other US companies in Drug Manufacturers - General with a 5y growth figure.

Quality

Moderate

Capacity to keep growing the dividend

Risk

Low

Signals of dividend-cut pressure

Trim

Moderate

How extended the valuation looks

Why Quality is 62

MRK against US companies in Drug Manufacturers - General (9)

Valuation against its own history

As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of MRK’s past readings.

P/E-59.5×P86, poor for this measure
Yield2.6%P64, neutral for this measure
FCF payout51.7%P11, good for this measure
Net debt / EBITDA33.02P100, poor for this measure
DGR 5y6.3%P54, neutral for this measure
ROIC-0.7%P43, neutral for this measure

Open valuation history

Forecast your income with the MRK dividend calculator

Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.